Alnylam Pharmaceuticals (NASDAQ:ALNY) was downgraded by investment analysts at BidaskClub from a “strong-buy” rating to a “buy” rating in a research note issued on Monday.
ALNY has been the topic of a number of other research reports. Zacks Investment Research upgraded shares of Alnylam Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, April 17th. Jefferies Financial Group restated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 2nd. Evercore ISI began coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 28th. They issued a “line” rating and a $143.00 target price on the stock. B. Riley restated a “buy” rating and issued a $200.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday, April 2nd. Finally, Stifel Nicolaus lowered their target price on shares of Alnylam Pharmaceuticals from $107.00 to $95.00 and set a “hold” rating on the stock in a report on Friday, May 4th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating, fifteen have given a buy rating and two have issued a strong buy rating to the stock. Alnylam Pharmaceuticals presently has an average rating of “Buy” and an average price target of $140.38.
Shares of NASDAQ ALNY traded down $1.57 during trading on Monday, hitting $106.23. 806,914 shares of the company traded hands, compared to its average volume of 948,109. Alnylam Pharmaceuticals has a fifty-two week low of $70.76 and a fifty-two week high of $153.99. The firm has a market capitalization of $10.84 billion, a P/E ratio of -19.60 and a beta of 2.67. The company has a current ratio of 14.61, a quick ratio of 14.61 and a debt-to-equity ratio of 0.02.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, May 3rd. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, beating the consensus estimate of ($1.47) by $0.06. Alnylam Pharmaceuticals had a negative net margin of 565.20% and a negative return on equity of 36.81%. The firm had revenue of $21.90 million for the quarter, compared to analyst estimates of $35.23 million. During the same quarter in the prior year, the business earned ($1.25) earnings per share. The business’s quarterly revenue was up 15.3% compared to the same quarter last year. equities research analysts forecast that Alnylam Pharmaceuticals will post -6.7 EPS for the current year.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating sold 1,562 shares of the company’s stock in a transaction dated Tuesday, March 20th. The shares were sold at an average price of $149.83, for a total value of $234,034.46. Following the completion of the sale, the senior vice president now directly owns 16,062 shares of the company’s stock, valued at approximately $2,406,569.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Yvonne Greenstreet sold 7,221 shares of the company’s stock in a transaction dated Monday, March 26th. The stock was sold at an average price of $136.54, for a total transaction of $985,955.34. Following the completion of the sale, the chief operating officer now directly owns 7,221 shares of the company’s stock, valued at $985,955.34. The disclosure for this sale can be found here. Corporate insiders own 3.70% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its position in shares of Alnylam Pharmaceuticals by 0.9% during the 1st quarter. BlackRock Inc. now owns 7,178,062 shares of the biopharmaceutical company’s stock valued at $854,909,000 after acquiring an additional 62,999 shares during the period. Baillie Gifford & Co. grew its position in shares of Alnylam Pharmaceuticals by 6.2% during the 1st quarter. Baillie Gifford & Co. now owns 3,834,213 shares of the biopharmaceutical company’s stock valued at $456,656,000 after acquiring an additional 223,199 shares during the period. Point72 Asset Management L.P. grew its position in shares of Alnylam Pharmaceuticals by 921.6% during the 1st quarter. Point72 Asset Management L.P. now owns 908,046 shares of the biopharmaceutical company’s stock valued at $108,148,000 after acquiring an additional 819,160 shares during the period. Geode Capital Management LLC grew its position in shares of Alnylam Pharmaceuticals by 13.4% during the 4th quarter. Geode Capital Management LLC now owns 747,646 shares of the biopharmaceutical company’s stock valued at $94,929,000 after acquiring an additional 88,119 shares during the period. Finally, Bridger Management LLC grew its position in shares of Alnylam Pharmaceuticals by 30.3% during the 4th quarter. Bridger Management LLC now owns 500,219 shares of the biopharmaceutical company’s stock valued at $63,553,000 after acquiring an additional 116,286 shares during the period. 90.21% of the stock is owned by hedge funds and other institutional investors.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia.
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.